- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.12.2025 | 672 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 18.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.12.2025ISIN NameAU000000WLD8 WELLARD... ► Artikel lesen | |
| 16.12.25 | XFRA 99B0: AUSSETZUNG/SUSPENSION | 292 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILQUIA PHARMA AB O.N.... ► Artikel lesen | |
| 17.11.25 | The observation status for QUIA PHARMA AB (publ) is updated | 277 | GlobeNewswire | On June 12, 2025, the shares in QUIA PHARMA AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
The... ► Artikel lesen | |
| QUIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 17.11.25 | Delisting of QUIA PHARMA AB (publ) from Nasdaq First North Growth Market | 320 | GlobeNewswire | According to item 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to item 1.4.2 of the Nasdaq First North... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 90,38 | 0,00 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 13,670 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| SOLID BIOSCIENCES | 8,330 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates | - Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,230 | 0,00 % | Hauptversammlung von Recursion Pharmaceuticals: Aktionäre stimmen allen Vorschlägen zu | ||
| MAPLIGHT THERAPEUTICS | 28,820 | 0,00 % | MapLight Therapeutics, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 27,870 | -0,36 % | Tango Therapeutics auf Rekordhoch: Aktie steigt auf 33,19 USD | ||
| TAYSHA GENE THERAPIES | 6,420 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| ANNEXON | 4,900 | 0,00 % | Annexon Biosciences: Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ||
| ODYSSEY THERAPEUTICS | 19,070 | 0,00 % | Odyssey Therapeutics Inc: Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 9,510 | 0,00 % | How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet | ||
| PRAXIS PRECISION MEDICINES | 282,15 | -0,06 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SANA BIOTECHNOLOGY | 3,150 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility | SEATTLE, May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold... ► Artikel lesen | |
| BRIDGEBIO ONCOLOGY THERAPEUTICS | 7,560 | 0,00 % | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress | Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,520 | -0,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,43 | 0,00 % | Kymera presents KT-621 phase 1 data in Japanese adults |
QUIA PHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QUIA PHARMA AB finden Sie auf Wallstreet Online.